Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 450 publications

Erdheim-Chester Disease Masquerading as Leukemia: Outwitting the Need for Transplant.

Erdheim-Chester Disease Masquerading as Leukemia: Outwitting the Need for Transplant.

Journal: Cureus
Published: October 15, 2025

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib.

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib.

Journal: JAAD case reports
Published: September 11, 2025

Molecular Interactions of Cobimetinib and Vemurafenib with Human Serum Albumin: a Comparative Biophysical and Computational Analysis.

Molecular Interactions of Cobimetinib and Vemurafenib with Human Serum Albumin: a Comparative Biophysical and Computational Analysis.

Journal: Molecular pharmaceutics
Published: July 15, 2025

Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation.

Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation.

Journal: Leukemia & lymphoma
Published: May 29, 2025

Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma.

Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma.

Journal: Journal of managed care & specialty pharmacy
Published: May 20, 2025

Novel Combination Therapy With Lenalidomide and Trametinib for Treatment-Resistant Xanthoma Disseminatum With Disabling Cutaneous and Synovial Involvement: A Case Report.

Novel Combination Therapy With Lenalidomide and Trametinib for Treatment-Resistant Xanthoma Disseminatum With Disabling Cutaneous and Synovial Involvement: A Case Report.

Journal: Cureus
Published: May 18, 2025

Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas.

Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas.

Journal: Life science alliance
Published: April 11, 2025

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.

Journal: Journal for immunotherapy of cancer
Published: April 01, 2025

Cutaneous Limited Langerhans Cell Histiocytosis Complicated by Late-onset Panhypopituitarism.

Cutaneous Limited Langerhans Cell Histiocytosis Complicated by Late-onset Panhypopituitarism.

Journal: JCEM case reports
Published: March 25, 2025

Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.

Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.

Journal: Cancer science
Published: March 19, 2025

Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis (2014-2023).

Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis (2014-2023).

Journal: Cancers
Published: March 16, 2025

Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial.

Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial.

Journal: Acta oncologica (Stockholm, Sweden)
Published: March 14, 2025
Showing 1-12 of 450

Last Updated: 10/31/2025